Multicenter Study Evaluating 12 Versus 24 Weeks Therapy With Peginterferon and Ribavirin for Hepatitis C Virus (HCV) Genotype 2 or 3
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00143000|
Recruitment Status : Completed
First Posted : September 2, 2005
Last Update Posted : April 7, 2008
|Condition or disease||Intervention/treatment||Phase|
|Hepatitis C Virus||Drug: Peginterferon alfa-2a 40KD and Ribavirin||Phase 4|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||392 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Multicenter Study Evaluating the Efficacy and Safety of 12 Weeks Versus 24 Weeks Peginterferon Alfa-2a 40KD Combination Therapy With Ribavirin in Interferon Naïve Patients With Chronic Hepatitis C Genotype 2 or 3 Infection|
|Study Start Date :||April 2004|
|Actual Study Completion Date :||October 2006|
- Sustained Viral Response (SVR) rate defined as percentage of patients with non-detectable HCV-RNA as measured by COBAS TaqMan 48™ (<50 IU/mL) at 24 weeks post completion of the 12 or 24 week treatment period.
- ALT measurements at 24 weeks post completion of the 12 or 24 week treatment period.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00143000
|Göteborg, Västra Götaland, Sweden, SE-413 45|
|Principal Investigator:||Gunnar Norkrans, Professor||Göteborg University|